Pfizer’s oncology business has delivered multiple clinical wins that underpin its value thesis for 2026. In December, the Phase 3 BRAFTOVI trial in combination with Mektovi achieved its primary endpoint of progression-free survival in patients with BRAFV600E‐mutant colorectal cancer, positioning the duo for potential regulatory filings in mid-2026. Meanwhile, PADCEV’s label expansion in combination with Keytruda for first-line urothelial carcinoma was supported by a 22-month median overall survival benefit versus chemotherapy in a 900-patient trial, setting the stage for peak incremental sales of $1.5 billion by 2028. These assets now represent three of Pfizer’s top five growth drivers, collectively projected to contribute over $4 billion in incremental revenue by 2030.

Pfizer’s investment in metabolic disease research has yielded two late-stage obesity candidates that could reshape its long-term growth profile. MET-097i, a once-weekly GLP-1/glucagon dual agonist, enters two global Phase 3 registrational studies in Q2 2026, each targeting 3,000 patients with BMI ≥30 kg/m2. Concurrently, an undisclosed oral small-molecule candidate for weight management has commenced a 250‐patient Phase 2b dose-finding trial, expected to report topline data in H1 2027. Given the obesity therapeutics market is forecast to exceed $30 billion by 2028, positive Phase 3 outcomes could drive a substantial re-rating of Pfizer’s multiple.

To support reinvestment in R&D and shareholder returns, Pfizer is executing an aggressive cost-remediation plan targeting $4.5 billion in annual savings by year-end 2026. Initiatives include site consolidation across manufacturing networks, a 15% reduction in non‐labor operating expenses, and renegotiated supplier contracts delivering $1.2 billion in supply-chain efficiencies. As a result, free cash flow is expected to rise from $12.8 billion in 2025 to approximately $15.3 billion in 2026, bolstering the company’s capacity for accelerated share repurchases and modest dividend hikes.